Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001876200-25-000004·MBX Biosciences, Inc.
Schedule 13D ownership disclosure
MBX Biosciences Inc
Common Stock, $0.0001 par value per share · CUSIP: 55287L101
Event date: 2025-09-26
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Norwest Venture Partners XVI, LPReported CIK 0001876200
Shares: 2,136,335.00 · Class: 4.8%
- Genesis VC Partners XVI, LLC
Shares: 2,136,335.00 · Class: 4.8%
- NVP Associates, LLCReported CIK 0001545692
Shares: 2,136,335.00 · Class: 4.8%
- Jeffrey CroweReported CIK 0001535261
Shares: 2,136,335.00 · Class: 4.8%
- Jon Erik KossowReported CIK 0001726084
Shares: 2,136,335.00 · Class: 4.8%
- Tiba AynechiReported CIK 0001669220
Shares: 2,140,989.00 · Class: 4.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001876200-25-000004
- Form type
- SCHEDULE 13D/A
- Filer
- MBX Biosciences, Inc.
- CIK
- CIK 1776111
- Filed
- Sep 30, 2025
- Reporting period
- Sep 26, 2025
- Description
- Schedule 13D beneficial ownership